a) Consulta externa de Reumatologia
Consulta de Triagem: para primeiras consultas referenciadas
Consulta de Reumatologia Geral
Consultas de Sub-Especialidade
Consultas Multidisciplinares
Outras Consultas
b) Unidade de Internamento de Reumatologia
c) Unidade de Técnicas de Reumatologia
d) Hospital de Dia de Reumatologia
e) Unidade de Reumatologia Pediátrica
f) Unidade de Doenças Ósseas Metabólicas
g) Unidade de Ensaios Clínicos de Reumatologia
h) Unidade de Ensaios Clínicos de Reumatologia
Ensaios Clínicos |
PROOF Patients with axial Spondyloarthritis: Multi-country registry of clinical characteristics, including radiographic progression, and burden of disease over 5 years in real-life setting |
PREVENT A randomized, double-blind, placebo-controlled multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long-term safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis. |
EARLY A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis |
BEYOND A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) |
SELECT-MONOTHERAPY A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX |
SELECT PSA 1 A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti Rheumtic Drug (csDMARDs) |
SELECT PSA 2 A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic |
M15-925 A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic |
BI 1293.10 An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis An exploratory maintenance trial evaluating the effect of BI655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment outside of 1293.10 |
KEEPsAKE2 A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic |
KEEPsAKE 1 A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy |
SELECT-GCA Phase 3 Safety and Efficacy Study of Upadacitinib in Subjects with Giant Cell Arteritis |
BIOP US A 3-arm, randomized, open-label, parallel active controlled, multicenter international study to compare the response of ultrasound-assessed synovitis to baricitinib, alone and combined with methotrexate versus etanercept in rheumatoid arthritis patients with inadequate response to methotrexate. Searching for synovium predictors of response. |
TWINSS A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial of CFZ533 in two distinct patient populations with Sjögren’s Syndrome to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously |
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy |
PRINTO Evidence Based Revision of the International League Against Rheumatism (ILAR) Classification Criteria for Juvenile Idiopathic Arthritis |
IM101240 An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis |
GO VISION Prospective observational study to examine the change of vision-related quality of life in subjects with spondyloarthritis during treatment with monthly subcutaneous injections of golimumab 50 mg according to EU label |
Cookie | Duração | Descrição |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |